Last reviewed · How we verify
NCT07268313
Complete Remission After Treatment With Biologics for Nasal Polyps
Phase 4 trial testing DUPIXENT® in Nasal Polyps in 66 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 3 April 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 6 locations across Denmark |
Drugs / interventions tested
- DUPIXENT®
- NUCALA®
- Dupi discontinuation
- Mepo discontinuation
Conditions studied
- Nasal Polyps — all drugs for Nasal Polyps →
Sponsor
Rigshospitalet, Denmark
Who can join
18 and older, any sex, with Nasal Polyps. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this RCT the investigators randomize patients who are treated with biologic treatment (Nucala or Dupixent) due to nasal polyps and have controlled disease within the last year to either stop treatment og continue as a control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07268313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DUPIXENT®
Trials testing the same drug.
- NCT04959448 — Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With · active not recruiting
- NCT04287621 — Registry of Asthma Patients Initiating DUPIXENT® · active not recruiting
Other recruiting trials for Nasal Polyps
Currently open trials in the same condition.
- NCT07245329 — Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps · NA · recruiting
- NCT05575037 — Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease · Phase 2 · active not recruiting
- NCT05094570 — Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP · Phase 4 · recruiting
- NCT05287841 — Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction? · NA · recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07268313 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 5 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07268313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing